Market Summary
USD27.53-0.13
Market Closedas of 21 Sep 2023, 09:55 am-0.47%
SUPN Stock Price
SUPN RSI Chart
SUPN Valuation
SUPN Price/Sales (Trailing)
SUPN Profitability
SUPN Fundamentals
SUPN Revenue
SUPN Earnings
Price Action
52 Week Range
27.4642.09
(Low)(High)
Last 7 days
-7.9%
Last 30 days
-11.9%
Last 90 days
-17.5%
Trailing 12 Months
-19.9%
SUPN Financial Health
SUPN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SUPN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-07 | Khattar Jack A. | sold (taxes) | -539,408 | 32.1 | -16,804 | president, ceo |
2023-09-07 | Bhatt Padmanabh P. | acquired | - | - | 2,500 | sr. vp of ip, cso |
2023-09-07 | Khattar Jack A. | acquired | - | - | 35,000 | president, ceo |
2023-09-07 | Bhatt Padmanabh P. | sold (taxes) | -37,942 | 32.1 | -1,182 | sr. vp of ip, cso |
2023-08-30 | Martin Tami Tillotson | acquired | 194,319 | 23.99 | 8,100 | sr. v.p., regulatory affairs |
2023-08-30 | Martin Tami Tillotson | sold | -259,200 | 32.00 | -8,100 | sr. v.p., regulatory affairs |
2023-08-25 | Martin Tami Tillotson | sold | -162,215 | 31.59 | -5,135 | sr. v.p., regulatory affairs |
2023-05-11 | DEC TIMOTHY C | acquired | - | - | 1,500 | senior vice-president & cfo |
2023-05-11 | Khattar Jack A. | sold (taxes) | -547,232 | 36.47 | -15,005 | president, ceo |
2023-05-11 | Khattar Jack A. | acquired | - | - | 31,250 | president, ceo |
Which funds bought or sold SUPN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | -401 | 1,954 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -87,256 | 425,109 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | new | - | 553,104 | 553,104 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.65 | -459,365 | 1,929,820 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 5.89 | -71,000 | 507,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.86 | -48,777 | 250,101 | -% |
2023-08-18 | Legato Capital Management LLC | unchanged | - | -137,646 | 670,609 | 0.09% |
2023-08-16 | CASTLEARK MANAGEMENT LLC | sold off | -100 | -4,017,180 | - | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -32.48 | -6,802,520 | 8,666,480 | -% |
2023-08-16 | Bridge City Capital, LLC | added | 0.06 | -386,272 | 1,888,610 | 0.89% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Supernus Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | armistice capital, llc | 8.06% | 4,356,000 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 10.71% | 5,789,960 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 17.8% | 9,604,073 | SC 13G/A | |
| Feb 15, 2022 | armistice capital, llc | 7.8% | 4,136,000 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 15.9% | 8,451,022 | SC 13G/A | |
| Jan 26, 2022 | blackrock inc. | 15.9% | 8,451,022 | SC 13G/A | |
| Feb 16, 2021 | armistice capital, llc | 5.9% | 3,120,000 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.06% | 5,298,078 | SC 13G/A | |
| Jan 25, 2021 | blackrock inc. | 16.9% | 8,912,801 | SC 13G | |
| Mar 12, 2020 | armistice capital, llc | 5.5% | 2,888,000 | SC 13G |
Recent SEC filings of Supernus Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 07, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 21, 2023 | 3 | Insider Trading | |
| Aug 21, 2023 | 4 | Insider Trading |
SUPN Fair Value
Loading...
Peers (Alternatives to Supernus Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.75% | 544.26% | -74.04 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -11.88% | -19.94% | 34.62 | 2.37 | 0.62% | -24.59% |
INVA | 832.3M | 244.3M | -4.13% | 4.68% | 4.22 | 3.41 | -39.50% | -4.99% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
ACRS | 479.1M | 31.2M | -7.77% | -52.62% | -4.55 | 15.37 | 407.54% | -26.47% |
OCUL | 269.4M | 54.6M | -13.04% | -44.44% | -2.97 | 4.93 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Supernus Pharmaceuticals News
Returns for SUPN
Cumulative Returns on SUPN
15.0%
10-Year Cumulative Returns
0.8%
7-Year Cumulative Returns
-10.8%
5-Year Cumulative Returns
7.4%
3-Year Cumulative Returns
Risks for SUPN
What is the probability of a big loss on SUPN?
95.8%
Probability that Supernus Pharmaceuticals stock will be more than 20% underwater in next one year
45.4%
Probability that Supernus Pharmaceuticals stock will be more than 30% underwater in next one year.
38.1%
Probability that Supernus Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SUPN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Supernus Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Supernus Pharmaceuticals
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -5.2% | 634 | 668 | 667 | 659 | 630 | 601 | 580 | 564 | 571 | 556 | 520 | 477 | 424 | 402 | 393 | 408 | 409 | 404 | 409 | 381 | 359 |
| Costs and Expenses | -0.9% | 614 | 619 | 621 | 641 | 578 | 527 | 494 | 441 | 424 | 398 | 347 | 306 | 269 | 250 | 244 | 261 | 264 | 265 | 264 | 242 | 235 |
| S&GA Expenses | -3.7% | 359 | 372 | 377 | 405 | 365 | 334 | 305 | 260 | 242 | 221 | 201 | 179 | 164 | 155 | 153 | 157 | 158 | 159 | 155 | 152 | 152 |
| R&D Expenses | 10.7% | 83.00 | 75.00 | 75.00 | 78.00 | 78.00 | 77.00 | 90.00 | 87.00 | 85.00 | 91.00 | 76.00 | 78.00 | 78.00 | 73.00 | 69.00 | 79.00 | 83.00 | 86.00 | 89.00 | 76.00 | 68.00 |
| EBITDA | -100.0% | - | 142 | 149 | 96.00 | 114 | 108 | 108 | 131 | 155 | 172 | 189 | 177 | 164 | 160 | 157 | 169 | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.21* | 0.22* | 0.15* | 0.18* | 0.18* | 0.19* | 0.23* | 0.27* | 0.31* | 0.36* | 0.37* | 0.39* | 0.40* | 0.40* | 0.41* | - | - | - | - | - |
| Interest Expenses | -43.3% | 1.00 | 2.00 | 3.00 | -9.50 | -5.30 | -1.64 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.00 | 14.00 | 12.00 | 11.00 | 1.00 | 9.00 | 5.00 |
| Earnings Before Taxes | -51.7% | 27.00 | 55.00 | 61.00 | 28.00 | 57.00 | 77.00 | 73.00 | 111 | 135 | 151 | 169 | 170 | 157 | 152 | 147 | 145 | 142 | 133 | 140 | 136 | 123 |
| EBT Margin | -100.0% | - | 0.08* | 0.09* | 0.04* | 0.09* | 0.13* | 0.13* | 0.20* | 0.24* | 0.27* | 0.32* | 0.36* | 0.37* | 0.38* | 0.38* | 0.36* | - | - | - | - | - |
| Net Income | -16.7% | 43.00 | 52.00 | 61.00 | 38.00 | 57.00 | 73.00 | 53.00 | 82.00 | 100 | 111 | 127 | 129 | 118 | 116 | 113 | 106 | 105 | 103 | 111 | 99.00 | 87.00 |
| Net Income Margin | -100.0% | - | 0.08* | 0.09* | 0.06* | 0.09* | 0.12* | 0.09* | 0.14* | 0.18* | 0.20* | 0.24* | 0.27* | 0.28* | 0.29* | 0.29* | 0.26* | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 161 | - | 138 | 120 | 93.00 | 125 | 108 | 118 | 163 | 135 | 145 | 177 | 114 | 140 | 131 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -27.8% | 1,293 | 1,792 | 1,703 | 1,693 | 1,695 | 1,640 | 1,689 | 1,555 | 1,573 | 1,507 | 1,504 | 1,510 | 1,491 | 1,190 | 1,160 | 1,107 | 1,064 | 1,025 | 978 | 923 | 853 |
| Current Assets | -52.1% | 424 | 883 | 734 | 664 | 625 | 569 | 602 | 668 | 639 | 586 | 630 | 552 | 557 | 557 | 473 | 427 | 391 | 420 | 493 | 391 | 285 |
| Cash Equivalents | -57.7% | 25.00 | 58.00 | 93.00 | 111 | 173 | 116 | 203 | 215 | 224 | 256 | 289 | 204 | 211 | 226 | 181 | 117 | 87.00 | 123 | 192 | 124 | 35.00 |
| Inventory | -0.6% | 91.00 | 91.00 | 92.00 | 83.00 | 85.00 | 89.00 | 86.00 | 60.00 | 58.00 | 50.00 | 48.00 | 42.00 | 35.00 | 24.00 | 27.00 | 26.00 | 26.00 | 27.00 | 26.00 | 23.00 | 21.00 |
| Net PPE | -2.9% | 14.00 | 15.00 | 15.00 | - | - | 17.00 | 17.00 | - | - | 38.00 | 38.00 | 17.00 | 18.00 | 18.00 | 17.00 | 10.00 | 4.00 | 4.00 | 4.00 | 7.00 | 5.00 |
| Goodwill | 0% | 117 | 117 | 117 | 117 | 115 | 115 | 118 | 40.00 | 78.00 | 78.00 | 78.00 | 89.00 | 88.00 | - | - | - | - | - | - | - | - |
| Liabilities | -57.6% | 373 | 880 | 816 | 840 | 854 | 811 | 873 | 745 | 787 | 753 | 759 | 801 | 825 | 576 | 565 | 550 | 541 | 545 | 525 | 501 | 462 |
| Current Liabilities | -65.5% | 253 | 732 | 688 | 726 | 736 | 285 | 315 | 235 | 283 | 241 | 245 | 300 | 269 | 168 | 161 | 150 | 144 | 152 | 161 | 138 | 104 |
| LT Debt, Current | - | - | - | - | 401 | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | - | - | - | - | - | - | - | 379 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | 0.9% | 920 | 912 | 886 | 853 | 841 | 828 | 816 | 810 | 786 | 754 | 745 | 709 | 666 | 613 | 595 | 557 | 523 | 480 | 453 | 422 | 390 |
| Retained Earnings | -0.2% | 497 | 498 | 481 | 456 | 454 | 446 | 380 | 377 | 356 | 332 | 326 | 296 | 256 | 221 | 200 | 166 | 138 | 105 | 86.00 | 61.00 | 33.00 |
| Additional Paid-In Capital | 1.9% | 424 | 416 | 408 | 401 | 390 | 383 | 434 | 429 | 424 | 416 | 409 | 403 | 399 | 392 | 388 | 384 | 379 | 374 | 370 | 365 | 362 |
| Shares Outstanding | 0% | 54.00 | 54.00 | 54.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 52.00 | 52.00 | 52.00 | 52.00 | 52.00 | 52.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -55.7% | 72.00 | 162 | 117 | 138 | 120 | 95.00 | 127 | 110 | 120 | 166 | 138 | 150 | 182 | 119 | 143 | 132 | 157 | 135 | 129 | 132 | 109 |
| Share Based Compensation | 9.0% | 22.00 | 20.00 | 18.00 | 17.00 | 16.00 | 18.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 16.00 | 16.00 | 15.00 | 14.00 | 13.00 | 12.00 | 11.00 | 10.00 | 10.00 |
| Cashflow From Investing | 81.6% | 169 | 93.00 | -216 | -91.77 | -15.24 | -80.45 | -81.91 | -108 | -114 | -141 | -34.70 | -64.61 | -61.66 | -19.24 | -157 | -143 | -109 | -465 | -413 | -466 | -513 |
| Cashflow From Financing | -524.6% | -389 | 92.00 | -10.48 | -150 | -155 | -154 | -130 | 9.00 | 7.00 | 6.00 | 4.00 | 2.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 10.00 | 376 | 376 | 378 |
SUPN Income Statement
2023-06-30Condensed Consolidated Statements of Earnings (Loss) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues | ||||
| Total revenues | $ 135,563 | $ 170,051 | $ 289,327 | $ 322,557 |
| Costs and expenses | ||||
| Cost of goods sold | 21,091 | 20,457 | 44,551 | 38,389 |
| Research and development | 24,379 | 16,385 | 45,591 | 37,224 |
| Selling, general and administrative | 86,782 | 100,476 | 172,379 | 190,935 |
| Amortization of intangible assets | 20,108 | 20,644 | 40,074 | 41,288 |
| Contingent consideration expense (gain) | 790 | 743 | (857) | 1,408 |
| Total costs and expenses | 153,150 | 158,705 | 301,738 | 309,244 |
| Operating earnings (loss) | (17,587) | 11,346 | (12,411) | 13,313 |
| Other income (expense) | ||||
| Interest expense | (910) | (1,810) | (2,415) | (3,752) |
| Interest and other income, net | 1,370 | 1,788 | 6,716 | 16,486 |
| Total other income (expense) | 460 | (22) | 4,301 | 12,734 |
| Earnings (loss) before income taxes | (17,127) | 11,324 | (8,110) | 26,047 |
| Income tax expense (benefit) | (16,296) | 3,459 | (24,227) | (7,434) |
| Net earnings (loss) | $ (831) | $ 7,865 | $ 16,117 | $ 33,481 |
| Earnings (loss) per share | ||||
| Basic (in dollars per share) | $ (0.02) | $ 0.15 | $ 0.30 | $ 0.63 |
| Diluted (in dollars per share) | $ (0.02) | $ 0.14 | $ 0.29 | $ 0.57 |
| Weighted average shares outstanding | ||||
| Basic (in shares) | 54,502,993 | 53,426,163 | 54,442,463 | 53,378,319 |
| Diluted (in shares) | 54,502,993 | 61,397,159 | 59,035,154 | 61,401,694 |
| Net product sales | ||||
| Revenues | ||||
| Total revenues | $ 128,336 | $ 165,459 | $ 268,911 | $ 312,923 |
| Royalty revenues | ||||
| Revenues | ||||
| Total revenues | $ 7,227 | $ 4,592 | $ 20,416 | $ 9,634 |
SUPN Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 24,706 | $ 93,120 |
| Marketable securities | 126,950 | 368,214 |
| Accounts receivable, net | 136,556 | 165,497 |
| Inventories, net | 90,560 | 91,541 |
| Prepaid expenses and other current assets | 44,766 | 15,779 |
| Total current assets | 423,538 | 734,151 |
| Long-term marketable securities | 37,478 | 93,896 |
| Property and equipment, net | 14,186 | 15,173 |
| Intangible assets, net | 662,389 | 702,463 |
| Goodwill | 117,019 | 117,019 |
| Other assets | 38,489 | 39,806 |
| Total assets | 1,293,099 | 1,702,508 |
| Current liabilities | ||
| Accounts payable and accrued liabilities | 83,044 | 96,342 |
| Accrued product returns and rebates | 148,826 | 151,665 |
| Convertible notes, net | 0 | 401,968 |
| Contingent consideration, current portion | 20,720 | 21,120 |
| Other current liabilities | 0 | 16,863 |
| Total current liabilities | 252,590 | 687,958 |
| Contingent consideration, long-term | 33,390 | 33,847 |
| Operating lease liabilities, long-term | 34,177 | 35,998 |
| Deferred income tax liabilities, net | 44,300 | 49,809 |
| Other liabilities | 8,734 | 8,692 |
| Total liabilities | 373,191 | 816,304 |
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 54,592,901 and 54,253,796 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 55 | 54 |
| Additional paid-in capital | 424,266 | 408,115 |
| Accumulated other comprehensive loss, net of tax | (1,775) | (3,210) |
| Retained earnings | 497,362 | 481,245 |
| Total stockholders’ equity | 919,908 | 886,204 |
| Total liabilities and stockholders’ equity | $ 1,293,099 | $ 1,702,508 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.